The migraine disability assessment (MIDAS) questionnaire in the primary-care setting

被引:0
作者
Dowson A.J. [1 ,4 ]
Sakai F. [2 ]
Brandes J. [3 ]
机构
[1] King's Headache Service, King's College Hospital, London
[2] Third Department of Internal Medicine (Neurology), Kitasato University School of Medicine, Kanagawa
[3] Vanderbilt University School of Medicine, Nashville, TN
[4] King's Headache Service, King's College Hospital, London, SE5 9RS, Denmark Hill
关键词
Migraine; Migraine Attack; Migraine Patient; Zolmitriptan; Chronic Daily Headache;
D O I
10.2165/00124363-200418060-00002
中图分类号
学科分类号
摘要
Migraine is a remarkably disabling condition, although unpredictable and heterogeneous in frequency, duration and severity. It can be difficult to manage in primary care where it is under-recognised, underdiagnosed and undertreated. Proposals have been made that migraine care could be improved by incorporating assessments of migraine impact into management strategies, and measuring headache-related disability can be used to assess the impact of migraine on people's lives and society. The Migraine Disability Assessment (MIDAS) questionnaire was developed from this research. MIDAS is a scientifically reliable and valid measure of migraine disability that can improve communication between patients and physicians, assess migraine severity and act as an outcome measure to monitor treatment efficacy. Perhaps the most important use of MIDAS is as an aid to public health initiatives on headache. MIDAS can be used to screen populations for headache-related disabilities and medical needs and be part of generalised migraine management guidelines in primary care in order to produce an individualised treatment plan for each patient. MIDAS can be used by physicians, pharmacists, nurses and patients. © 2004 Adis Data Information BV. All rights reserved.
引用
收藏
页码:325 / 335
页数:10
相关论文
共 76 条
[1]  
Breslau N., Rasmussen B.K., The impact of migraine: Epidemiology, risk factors, and co-morbidities, Neurology, 56, 1 SUPPL., pp. 4-12, (2001)
[2]  
Osterhaus J.T., Townsend R.J., Gandek B., Et al., Measuring the functional status and well-being of patients with migraine headache, Headache, 34, pp. 337-343, (1994)
[3]  
Ferrari M.D., The economic burden of migraine to society, Pharmacoeconomics, 13, pp. 667-676, (1998)
[4]  
Lipton R.B., Goadsby P.J., Sawyer J.P.C., Et al., Migraine: Diagnosis and assessment of disability, Rev Contemp Pharmacother, 11, pp. 63-73, (2000)
[5]  
Silberstein S.D., Lipton R.B., Chronic daily headache, Curr Opin Neurol, 13, pp. 277-283, (2000)
[6]  
Dowson A.J., Analysis of the patients attending a specialist UK headache clinic over a 3-year period, Headache, 43, pp. 14-18, (2003)
[7]  
Lipton R.B., Stewart W.F., Diamond S., Et al., Prevalence and burden of migraine in the United States: Data from the American migraine study II, Headache, 41, pp. 646-657, (2002)
[8]  
Lipton R.B., Diamond S., Reed M., Et al., Migraine diagnosis and treatment: Results from the American migraine study II, Headache, 41, pp. 638-645, (2001)
[9]  
Silberstein S.D., Practice parameter: Evidence-based guidelines for migraine headache (an evidence-based review), Neurology, 55, pp. 754-762, (2000)
[10]  
Bedell A.W., Cady R.K., Diamond M.L., Et al., Patient-centered Strategies for Effective Management of Migraine, (2000)